Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.71 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.61 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.59 |
| ▸ | HTT | P42858 | 2/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.59 |
| ▸ | FBP1 | P09467 | 2/20 | 0.58 |
| ▸ | GAK | O14976 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.56 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1507485 | 0.99 | EGFR (0.69) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL1507420 | 0.91 | EGFR (0.71) | EGFRABCG2ALKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL1507467 | 0.90 | EGFR (0.69) | EGFRABCG2ALKALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL8683240 | 0.85 | EGFR (0.68) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL18349251 | 0.84 | EGFR (0.77) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL28687823 | 0.83 | ABCG2 (0.61) | EGFRABCG2 | |
| SCHEMBL1192454 | 0.83 | EGFR (1.00) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL3244621 | 0.83 | EGFR (1.00) | EGFRABCG2ALKERBB2 | |
| SCHEMBL8871973 | 0.83 | EGFR (0.83) | EGFRABCG2ALKALDH1A1MAPT | |
| SCHEMBL4587413 | 0.83 | EGFR (0.83) | EGFRABCG2ALKALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2016-10-20 | — | — | US | claimed |
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2015-03-26 | — | — | US | claimed |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | GENENTECH INC (US) | 2015-02-26 | — | — | US | claimed |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | SLIWKOWSKI MARK X (US) | 2012-10-04 | — | — | US | claimed |
| US-8163287-B2 | Combination therapy of her expressing tumors | GENENTECH, INC. (US) | 2012-04-24 | — | — | US | claimed |
| EP-2344543-A2 | TREATMENT METHOD | Genentech, Inc. (US) | 2011-07-20 | — | — | EP | claimed |
| JP-2011513427-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2295415-A1 | Quinazoline derivatives | OSI Pharmaceuticals, Inc. (US) | 2011-03-16 | — | — | EP | claimed |
| EP-2257293-A2 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | Genentech, Inc. (US) | 2010-12-08 | — | — | EP | claimed |
| WO-2010045345-A2 | TREATMENT METHOD | GENENTECH, INC. (US) | 2010-04-22 | — | — | WO | claimed |
| WO-2007013950-A9 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH INC (US) | 2007-03-29 | — | — | WO | claimed |
| WO-2007013950-A2 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | GENENTECH, INC. (US) | 2007-02-01 | — | — | WO | claimed |
| US-20070020261-A1 | Combination therapy of her expressing tumors | GENENTECH, INC. | 2007-01-25 | — | — | US | claimed |
| EP-0817775-B1 | QUINAZOLINE DERIVATIVES | PFIZER (US) | 2001-09-12 | — | — | EP | claimed |
| EP-1110953-A1 | Quinazoline derivatives | PFIZER INC. (US) | 2001-06-27 | — | — | EP | claimed |
| CN-1066142-C | Quinazoline derivatives | PFIZER (US) | 2001-05-23 | — | — | CN | claimed |
| US-5747498-A | Alkynyl and azido-substituted 4-anilinoquinazolines | PFIZER INC. (US) | 1998-05-05 | — | — | US | claimed |
| EP-0817775-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1998-01-14 | — | — | EP | claimed |
| CN-1137037-A | Quinazoline derivatives | PFIZER (US) | 1996-12-04 | — | — | CN | claimed |
| WO-1996030347-A1 | QUINAZOLINE DERIVATIVES | PFIZER INC. (US) | 1996-10-03 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150086545-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABCG2 3176/4885ALK 119/4885 |
| US-20070020261-A1 | Combination therapy of her expressing tumors | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABCG2 3176/4885ALK 119/4885 |
| US-20160303127-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ABCG2 2367/4885ALK 10/4885 |
| US-20150056207-A1 | COMBINATION THERAPY WITH C-MET AND EGFR ANTAGONISTS | MET, EGFR, ERBB2 | EGFR 2/4885ABCG2 2367/4885ALK 10/4885 |
| US-20120251530-A1 | COMBINATION THERAPY OF HER EXPRESSING TUMORS | ERBB2, EGFR, ERBB3 | EGFR 2/4885ABCG2 3176/4885ALK 119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.